158 related articles for article (PubMed ID: 37301546)
21. A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients.
Zhang WT; Gong YM; Zhang CY; Pan JS; Huang T; Li YX
Biomed Res Int; 2022; 2022():9196540. PubMed ID: 36105937
[TBL] [Abstract][Full Text] [Related]
22. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
23. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
Front Genet; 2022; 13():923737. PubMed ID: 35991547
[No Abstract] [Full Text] [Related]
24. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
25. GDF15 expression in glioma is associated with malignant progression, immune microenvironment, and serves as a prognostic factor.
Guo L; Chen Y; Hu S; Gao L; Tang N; Liu R; Qin Y; Ren C; Du S
CNS Neurosci Ther; 2022 Jan; 28(1):158-171. PubMed ID: 34697897
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
27. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
28. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
Front Genet; 2022; 13():969856. PubMed ID: 36226187
[No Abstract] [Full Text] [Related]
31. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
Front Genet; 2022; 13():962028. PubMed ID: 36061184
[No Abstract] [Full Text] [Related]
32. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
[TBL] [Abstract][Full Text] [Related]
33. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
[TBL] [Abstract][Full Text] [Related]
34. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
Liu Z; Miao J
Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
[TBL] [Abstract][Full Text] [Related]
36. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
38. Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma.
Zhang Y; Zhang C; Yang Y; Wang G; Wang Z; Liu J; Zhang L; Yu Y
Front Cell Dev Biol; 2022; 10():862493. PubMed ID: 35547808
[No Abstract] [Full Text] [Related]
39. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
40. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]